![Naamit Sher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Naamit Sher worked as the VP of Drug Development & Regulatory Affairs at Vascular Biogenics Ltd. She was also the Director of Quality Control & Quality Assurance at Interpharm Laboratories Ltd. and the Head of QC Laboratories at Teva Pharmaceutical Industries Ltd. Additionally, she held the title of Principal at Teva North America.
Dr. Sher received her undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.
Eerdere bekende functies van Naamit Sher
| Bedrijven | Functie | Einde |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01-01-2006 |
Teva North America | Corporate Officer/Principal | - |
Interpharm Laboratories Ltd.
 Interpharm Laboratories Ltd. BiotechnologyHealth Technology Develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases | Corporate Officer/Principal | - |
| NOTABLE LABS, LTD. | Algemeen Adviseur | - |
Opleiding van Naamit Sher
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
8
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Teva North America | |
Interpharm Laboratories Ltd.
Interpharm Laboratories Ltd. BiotechnologyHealth Technology Develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Develops novel treatments for atherosclerosis and cancer | Health Technology |
Kies MarketScreener 
